@tra418 , I also have the ATM mutation with my pancreatic cancer. I understand it has similar impact on DNA Damage Repair (DDR) as other gene mutations like BRCA1, BRCA2, PALB2, and is sometimes treated with drugs (PARP Inhibitors?) targeting the DDR function.

@gamaryanne , I think the KRAS mutation is more common in PC. I've seen trials and stories specifically targeting KRAS, but the only link I have handy is this one: https://www.nbcnews.com/health/health-news/gene-therapy-pancreatic-cancer-experimental-approach-shrank-tumors-one-rcna31437 . That might be the same treatment / story originating from U of PA, but with another researcher working on it in Oregon.

I've heard oncologists refer to "tumor agnostic" treatments in the context of modern, targeted therapies. Instead of focusing so much on the organ where the primary tumor originated and the traditional "cancer type," they're focusing on the "cancer biology" -- specifically mutations in the DNA and drugs that will target those cancer cells wherever they may roam.

"May we live in interesting times!" 😉